Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

NCT03551626 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

552

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

Novartis Pharmaceuticals